SKNY — LIR Life Sciences Balance Sheet
0.000.00%
Last trade - 00:00- CA$3.73m
- CA$3.53m
Annual balance sheet for LIR Life Sciences, fiscal year end - April 30th, CAD millions except per share, conversion factor applied.
2021 January 31st | 2022 January 31st | 2024 April 30th | 2025 April 30th | 2026 April 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 15 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Short Term Investments | 0.522 | 0.456 | 2.69 | 1.6 | 0.597 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0 | 0 | 0.212 | 0.037 | 0.067 |
| Prepaid Expenses | |||||
| Total Current Assets | 0.522 | 0.456 | 2.92 | 1.65 | 0.837 |
| Net Property, Plant And Equipment | 0 | 0.171 | 5.62 | 0 | — |
| Total Assets | 0.522 | 0.627 | 8.53 | 1.65 | 0.837 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Current Liabilities | 0.007 | 0.052 | 0.077 | 0.072 | 0.18 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 0.007 | 0.052 | 0.098 | 0.072 | 0.18 |
| Common Stock | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 0.515 | 0.575 | 8.44 | 1.58 | 0.656 |
| Total Liabilities & Shareholders' Equity | 0.522 | 0.627 | 8.53 | 1.65 | 0.837 |
| Total Common Shares Outstanding |